Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Find studies

Showing 451–475 of 653 studies of type cross-sectional study · free to read (page 19 of 27) · 31,380 in the whole library · How the 0–100 score works

Download bibliography of the first 500 of these studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

This study suggests that violence is a significant phenomenon and that all health workers, especially nurses, are at risk of suffering aggressive assaults. 4 key findings →

Design: cross-sectional Evidence: low

Early increases in plasma NfL may reflect early white matter microstructural changes prior to dementia in DS. 2 key findings →

Design: cross-sectional Evidence: low

Neuropathological measures of increased tau phosphorylation across the Down syndrome lifespan

✓ Peer-reviewed alzhub usefulness score 48 out of 100. Acta neuropathologica 2026-03-22

Individuals with Down syndrome (DS) have an increased risk of developing Alzheimer disease (AD), with nearly all individuals exhibiting AD neuropathology, including amyloid beta (Aβ) plaques and neurofibrillary tangles (NFT), by age 40 years. 5 key findings →

Design: cross-sectional Participants: 98 Evidence: low

Subtype and Stage Inference (SuStaIn) is an unsupervised learning algorithm that uniquely enables the identification of subgroups of individuals with distinct pseudo-temporal disease progression patterns from cross-sectional datasets. 4 key findings →

Design: cross-sectional Evidence: low

A comprehensive outcome monitoring system to monitor the quality and safety of care and variation for HCP recipients was developed. 1 key finding →

Design: cross-sectional Participants: 68 Evidence: low

Older age was associated with greater odds of abnormal p-Tau217 (odds ratio [OR] 1.08 per year, 95% CI 1.07–1.09), as was APOE ε4 carrier status (OR 3.32, 95% CI 2.65–4.17). 5 key findings →

Design: cross-sectional Participants: 2,798 Evidence: moderate

Early detection of cognitive decline in older adults is essential for implementing timely interventions. 4 key findings →

Design: cross-sectional Participants: 90 Evidence: low

Caregivers’ burden analytics: combining variables from patients with dementia and their caregivers

✓ Peer-reviewed alzhub usefulness score 48 out of 100. BMC Geriatrics 2025-08-14

One hundred and fifty rules were found for caregivers with a moderate to severe burden, and these rules can be further summarized into twenty general rules. 5 key findings →

Design: cross-sectional Participants: 585 Evidence: low

Having three or more vascular risk factors (odds ratio = 1.23, 95% confidence interval [1.04-1.47]), actively smoking (odds ratio = 1.54, 95% confidence interval [1.29-1.82]), being overweight (odds ratio = 1.46, 95% confidence interval [1.22-1.74]), and having diabetes (odds ratio = 1.29, 95% confidence interval [1.09-1.53]) were associated with higher odds of subjective cognitive decline. 2 key findings →

Design: cross-sectional Evidence: low

Cholinergic degeneration and early cognitive signs in prodromal Lewy body dementia

✓ Peer-reviewed alzhub usefulness score 48 out of 100. Alzheimer s & Dementia 2025-02-01

cBF volume declined at comparable rates in iRBD-to-PD and iRBD-to-DLB converters, but atrophy was more severe at DLB phenoconversion. cBF atrophy correlated with attention, executive, and memory deficits. 5 key findings →

Design: cross-sectional Evidence: moderate

Little is known about the dysbiosis of the gut microbiome in patients with mild cognitive impairment (MCI) potentially at risk for the development of Alzheimer's disease (AD). 5 key findings →

Design: cross-sectional Participants: 14 Evidence: moderate

< 0.001). Receiver operating characteristic (ROC) analysis identified right hippocampal MD and t-tau as optimal classifiers for AD. 4 key findings →

Design: cross-sectional Evidence: low

BackgroundOdor identification deficits predict Alzheimer's disease (AD) in epidemiological studies. 5 key findings →

Design: cross-sectional Participants: 600 Evidence: low

To the Editor: The standardized management of pain–agitation–delirium (PAD) represents a fundamental component of clinical practice in intensive care units (ICUs).[1] Evidence-based analgesia and sedation strategies not only alleviate patients’ physiological discomfort and psychological distress, but also significantly reduce mechanical ventilation duration, improve long-term prognosis, and optimize healthcare resource allocation.[1,2] Equally crucial is delirium management, as evidenced by studies demonstrating that delirium duration independently predicts mortality risk, hospital stay length, healthcare expenditures, and acquired dementia incidence.[3] Although existing studies have explored PAD management practices, most rely on clinicians’ subjective recall that may distort objective clinical realities and fail to reflect distinctive characteristics.[4] Therefore, this nationwide multicenter cross-sectional study, initiated by the Critical Care Analgesia and Sedation Quality Control Subspecialty Group under the China National Center for Medical Quality Control in Critical Care Medicine, aims to investigate the current status of PAD management in China. 5 key findings →

Design: cross-sectional Participants: 2,627 Evidence: moderate

Cerebral small vessel disease (cSVD) is characterised by white matter hyperintensities (WMH) and contributes to stroke and dementia. 5 key findings →

Design: cross-sectional Participants: 60 Evidence: low

Among 225 patients (mean age 65.4 years, 54.2% male), MCR prevalence was 16.4%. 5 key findings →

Design: cross-sectional Participants: 225 Evidence: low

Although clinical routine focuses on dichotomous and visual interpretation of amyloid PET, regional image assessment in research settings may yield additional opportunities. 5 key findings →

Design: cross-sectional Evidence: moderate

Elevated microglial activation in the right amygdala-entorhinal-hippocampal complex of App NL-G-F mice is associated with better spatial learning. 5 key findings →

Design: cross-sectional Evidence: low

Our findings suggest AD-type tau is not higher in LLD compared to non-depressed, cognitively unimpaired older adults and appears unlikely to contribute to lower gray matter volume in LLD, further underscoring the need to distinguish major depressive disorder from depressive symptoms occurring in early AD. 5 key findings →

Design: cross-sectional Participants: 102 Evidence: low

IL-6 levels were negatively associated with performance on the MMSE in this multiethnic cohort. 5 key findings →

Design: cross-sectional Evidence: moderate

There is a need for early, objective markers of Alzheimer's disease (AD)-related synapse dysfunction in adults with Down syndrome (DS). 1 key finding →

Design: cross-sectional Participants: 131 Evidence: moderate

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled.

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 31,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 31,380 records, built mostly from automated pulls of Europe PMC (65.6% of the library) and OpenAlex (16.2%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,048 records (3.3% of the library) are not peer-reviewed — 973 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed    Where this research is being discussed: events